Innovation

INVEST IN THE FUTURE

Facts & Figures

R&D at Evonik

R&D expenses (2021)

€464 million

R&D ratio

3.1%

No. of new patent applications filed (2021)

280

Patents held and applications filed

approx. 24,000

Registered/pending trademarks

approx. 7,350

R&D employees

approx. 2,600

R&D locations

more than 30

Evonik protects new products and processes through its patent strategy. The value and quality of our patent portfolio have increased steadily in recent years. We submitted 280 new patent applications in 2021, and R&D expenses increased by 7 percent to €464 million. Our R&D projects are managed using the multi-step Idea-to-Profit process developed by Evonik to support the systematic development of projects right up to profitable commercialization.

Our innovation pipeline comprises completely new business options as well as activities to secure and enhance the prospects of existing business operations. Alongside our product and process innovations, the focus includes business models and system innovations. Our project portfolio is aligned to the differing strategies of the various business lines, and we focus on growth areas with high sustainability benefits.

Evonik’s global R&D network comprises more than 30 locations with approximately 2,600 R&D employees.

In addition, Evonik gains access to potential new sources of business through its corporate venture capital activities. We invest specifically in specialized technology funds and start-ups of strategic relevance to Evonik. In this way, we gain insights into innovative developments at a very early stage. We work with our partners on projects to develop new products and technologies and increase the pace of innovation at Evonik. Around 40 investments have been made since 2012. One success story is JeNaCell, a biotech start-up in which Evonik invested in 2015. The nature-identical material developed by JeNaCell is used in medical technology and dermatology for the treatment of wounds and burns as well as in hydroactive skin care. We acquired all shares in JeNaCell in August 2021. 

More information: